Advertisement

Inflammatory breast cancer: early recognition and diagnosis is critical

Published:April 09, 2021DOI:https://doi.org/10.1016/j.ajog.2021.04.217
      Inflammatory breast cancer is a rare and aggressive malignancy that is often initially misdiagnosed because of its similar presentation to more benign breast pathologies such as mastitis, resulting in treatment delays. Presenting symptoms of inflammatory breast cancer include erythema, skin changes such as peau d’ orange or nipple inversion, edema, and warmth of the affected breast. The average age at diagnosis is younger than in noninflammatory breast cancer cases. Known risk factors include African American race and obesity. Diagnostic criteria include erythema occupying at least one-third of the breast, edema, peau d’ orange, and/or warmth, with or without an underlying mass; a rapid onset of <3 months; and pathologic confirmation of invasive carcinoma. Treatment of inflammatory breast cancer includes trimodal therapy with chemotherapy, surgery, and radiation. An aggressive surgical approach that includes a modified radical mastectomy enhances survival outcomes. Although the outcomes for patients with inflammatory breast cancer are poor compared with those of patients with noninflammatory breast cancer, patients with inflammatory breast cancer who complete trimodal therapy have a favorable locoregional control rate, underscoring the importance of a prompt diagnosis of this serious but treatable disease. Obstetrician-gynecologists and other primary care providers must recognize the signs and symptoms of inflammatory breast cancer to make a timely diagnosis and referral for specialized care.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Susan G.
        • Komen Breast Cancer Foundation
        Inflammatory breast cancer.
        (Available at:)
        • Hance K.W.
        • Anderson W.F.
        • Devesa S.S.
        • Young H.A.
        • Levine P.H.
        Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.
        J Natl Cancer Inst. 2005; 97: 966-975
        • Fouad T.M.
        • Kogawa T.
        • Liu D.D.
        • et al.
        Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
        Breast Cancer Res Treat. 2015; 152: 407-416
        • National Cancer Institute Surveillance
        Epidemiology, and End Results Program. Cancer stat facts: female breast cancer.
        (Available at:)
        https://seer.cancer.gov/statfacts/html/breast.html
        Date: 2019
        Date accessed: December 1, 2019
        • Masuda H.
        • Brewer T.M.
        • Liu D.D.
        • et al.
        Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
        Ann Oncol. 2014; 25: 384-391
        • Anderson W.F.
        • Schairer C.
        • Chen B.E.
        • Hance K.W.
        • Levine P.H.
        Epidemiology of inflammatory breast cancer (IBC).
        Breast Dis. 2005-2006; 22: 9-23
        • Chang S.
        • Buzdar A.U.
        • Hursting S.D.
        Inflammatory breast cancer and body mass index.
        J Clin Oncol. 1998; 16: 3731-3735
        • Stecklein S.R.
        • Reddy J.P.
        • Wolfe A.R.
        • et al.
        Lack of breastfeeding history in parous women with inflammatory breast cancer predicts poor disease-free survival.
        J Cancer. 2017; 8: 1726-1732
        • Fouad T.M.
        • Ueno N.T.
        • Yu R.K.
        • et al.
        Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): a comprehensive analysis of the IBC registry at the University of Texas MD Anderson Cancer Center.
        PLoS One. 2018; 13e0204372
        • Moslehi R.
        • Freedman E.
        • Zeinomar N.
        • Veneroso C.
        • Levine P.H.
        Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study.
        BMC Cancer. 2016; 16: 334
        • Gutierrez Barrera A.M.
        • Fouad T.M.
        • Song J.
        • et al.
        BRCA mutations in women with inflammatory breast cancer.
        Cancer. 2018; 124: 466-474
        • Dawood S.
        • Merajver S.D.
        • Viens P.
        • et al.
        International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.
        Ann Oncol. 2011; 22: 515-523
        • Ueno N.T.
        • Espinosa Fernandez J.R.
        • Cristofanilli M.
        • et al.
        International consensus on the clinical management of inflammatory breast cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.
        J Cancer. 2018; 9: 1437-1447
        • Abeywardhana D.Y.
        • Nascimento V.C.
        • Dissanayake D.
        • et al.
        Review of ultrasound appearance in inflammatory breast cancer: a pictorial essay.
        J Med Imaging Radiat Oncol. 2016; 60: 83-87
        • Raghav K.
        • French J.T.
        • Ueno N.T.
        • et al.
        Inflammatory breast cancer: a distinct clinicopathological entity transcending histological distinction.
        PLoS One. 2016; 11e0145534
        • Rueth N.M.
        • Lin H.Y.
        • Bedrosian I.
        • et al.
        Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database.
        J Clin Oncol. 2014; 32: 2018-2024
        • DeSnyder S.M.
        • Mittendorf E.A.
        • Le-Petross C.L.
        • et al.
        Prospective feasibility trial of sentinel lymph node biopsy in the setting of inflammatory breast cancer.
        Clin Breast Cancer. 2018; 18: e73-e77
        • Akay C.L.
        • Ueno N.T.
        • Chisholm G.B.
        • et al.
        Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer.
        Cancer. 2014; 120: 1319-1328
        • Low J.A.
        • Berman A.W.
        • Steinberg S.M.
        • Danforth D.N.
        • Lippman M.E.
        • Swain S.M.
        Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy.
        J Clin Oncol. 2004; 22: 4067-4074
        • Tsai C.J.
        • Li J.
        • Gonzalez-Angulo A.M.
        • et al.
        Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy.
        Am J Clin Oncol. 2015; 38: 242-247
        • Gianni L.
        • Eiermann W.
        • Semiglazov V.
        • et al.
        Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
        Lancet Oncol. 2014; 15: 640-647
        • Bristol I.J.
        • Woodward W.A.
        • Strom E.A.
        • et al.
        Locoregional treatment outcomes after multimodality management of inflammatory breast cancer.
        Int J Radiat Oncol Biol Phys. 2008; 72: 474-484